Bellerophon Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Bellerophon Therapeutics

31/03/2023 16:27

* Bellerophon Therapeutics Inc  BLPH.OQ  reported a
quarterly
adjusted loss of 53 cents​​ per share for the quarter ended in
December. The mean expectation of two analysts for the quarter
was for a loss of 48 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Bellerophon Therapeutics Inc's reported EPS for the
quarter was
a loss of 53 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Bellerophon Therapeutics Inc shares had risen by 728.9%
this
quarter.
    * The company reported a quarterly loss of $5.02 million.
    * Wall Street's median 12-month price target for Bellerophon
Therapeutics Inc is $24.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 31 at 03:27 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.48          -0.53          Missed
 Sep. 30 2022      -0.58          -0.53          Beat
 Jun. 30 2022      -0.60          -0.43          Beat
 Mar. 31 2022      -0.54          -0.59          Missed